Baek Jang-Hyun
Department of Neurology, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, Korea.
Neurointervention. 2023 Mar;18(1):9-22. doi: 10.5469/neuroint.2023.00031. Epub 2023 Feb 22.
A clinical decision on the treatment of asymptomatic carotid stenosis is challenging, unlike symptomatic carotid stenosis. Carotid artery stenting (CAS) has been recommended as an alternative to carotid endarterectomy (CEA) based on the finding that the efficacy and safety of CAS were comparable to CEA in randomized trials. However, in some countries, CAS is often performed more frequently than CEA for asymptomatic carotid stenosis. Moreover, it has been recently reported that CAS is not superior to the best medical treatment in asymptomatic carotid stenosis. Due to these recent changes, the role of CAS in asymptomatic carotid stenosis should be revisited. When determining the treatment for asymptomatic carotid stenosis, one should consider several clinical factors including stenosis degree, patient life expectancy, stroke risk by medical treatment, availability of a vascular surgeon, high risk for CEA or CAS, and insurance coverage. This review aimed to present and pragmatically organize the information that is necessary for a clinical decision on CAS in asymptomatic carotid stenosis. In conclusion, although the traditional benefit of CAS is being revisited recently, it seems too early to conclude that CAS is no longer beneficial under intense and systemic medical treatment. Instead, a treatment strategy with CAS should evolve to select eligible or medically high-risk patients more precisely.
与有症状的颈动脉狭窄不同,对无症状颈动脉狭窄进行临床治疗决策具有挑战性。基于随机试验中颈动脉支架置入术(CAS)的疗效和安全性与颈动脉内膜切除术(CEA)相当这一发现,CAS已被推荐作为CEA的替代方案。然而,在一些国家,对于无症状颈动脉狭窄,CAS的实施频率往往高于CEA。此外,最近有报道称,在无症状颈动脉狭窄中,CAS并不优于最佳药物治疗。由于这些最新变化,应重新审视CAS在无症状颈动脉狭窄中的作用。在确定无症状颈动脉狭窄的治疗方案时,应考虑几个临床因素,包括狭窄程度、患者预期寿命、药物治疗的中风风险、血管外科医生的可及性、CEA或CAS的高风险以及保险覆盖范围。本综述旨在呈现并切实整理无症状颈动脉狭窄中CAS临床决策所需的信息。总之,尽管最近人们对CAS的传统益处进行了重新审视,但在强化和系统的药物治疗下就得出CAS不再有益的结论似乎还为时过早。相反,采用CAS的治疗策略应不断发展,以便更精确地选择符合条件或药物治疗高风险的患者。